We are committed to serving the best interests of our shareholders. The investor pages that follow are your resource for financial information about Catalyst Biosciences, Inc.
NASDAQ: CBIO$3.900.13 (3.23%)May 22, 20172:47 p.m. ET
Delayed at least 15 minutes
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press ReleasesMay 11, 2017Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate UpdateApril 12, 2017Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment OptionApril 11, 2017Key Milestone Reached in Catalyst’s Subcutaneous Factor IX ProgramView all press releases »
Reverse Stock Split
|For the 1 for 15 Reverse Stock Split Tax Form, click here|
Targacept Special Dividend
|For the FAQ and additional information, click here.|
Catalyst Biosciences, Inc.
Red House Consulting, LLC